Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis.

Rivas-Santiago B, Rivas Santiago CE, Castañeda-Delgado JE, León-Contreras JC, Hancock RE, Hernandez-Pando R.

Int J Antimicrob Agents. 2013 Feb;41(2):143-8. doi: 10.1016/j.ijantimicag.2012.09.015. Epub 2012 Nov 8.

PMID:
23141114
2.

Ability of innate defence regulator peptides IDR-1002, IDR-HH2 and IDR-1018 to protect against Mycobacterium tuberculosis infections in animal models.

Rivas-Santiago B, Castañeda-Delgado JE, Rivas Santiago CE, Waldbrook M, González-Curiel I, León-Contreras JC, Enciso-Moreno JA, del Villar V, Mendez-Ramos J, Hancock RE, Hernandez-Pando R.

PLoS One. 2013;8(3):e59119. doi: 10.1371/journal.pone.0059119. Epub 2013 Mar 21.

3.

Cationic amphipathic D-enantiomeric antimicrobial peptides with in vitro and ex vivo activity against drug-resistant Mycobacterium tuberculosis.

Lan Y, Lam JT, Siu GK, Yam WC, Mason AJ, Lam JK.

Tuberculosis (Edinb). 2014 Dec;94(6):678-89. doi: 10.1016/j.tube.2014.08.001. Epub 2014 Aug 12.

PMID:
25154927
4.

In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.

Lu J, Yue J, Wu J, Luo R, Hu Z, Li J, Bai Y, Tang Z, Xian Q, Zhang X, Wang H.

Pharmacology. 2010;85(6):365-71. doi: 10.1159/000299795. Epub 2010 Jun 8.

PMID:
20530976
5.

In vitro activity of PR-39, a proline-arginine-rich peptide, against susceptible and multi-drug-resistant Mycobacterium tuberculosis.

Linde CM, Hoffner SE, Refai E, Andersson M.

J Antimicrob Chemother. 2001 May;47(5):575-80.

PMID:
11328767
6.

[Recent progress in mycobacteriology].

Okada M, Kobayashi K.

Kekkaku. 2007 Oct;82(10):783-99. Japanese.

PMID:
18018602
7.

Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo.

Koga T, Fukuoka T, Doi N, Harasaki T, Inoue H, Hotoda H, Kakuta M, Muramatsu Y, Yamamura N, Hoshi M, Hirota T.

J Antimicrob Chemother. 2004 Oct;54(4):755-60. Epub 2004 Sep 3.

PMID:
15347635
8.

Therapeutic efficacy of liposomes containing 4-(5-pentadecyl-1,3,4-oxadiazol-2-yl)pyridine in a murine model of progressive pulmonary tuberculosis.

Mata-Espinosa D, Molina-Salinas GM, Barrios-Payán J, Navarrete-Vázquez G, Marquina B, Ramos-Espinosa O, Bini EI, Baeza I, Hernández-Pando R.

Pulm Pharmacol Ther. 2015 Jun;32:7-14. doi: 10.1016/j.pupt.2015.03.004. Epub 2015 Apr 2.

PMID:
25843004
9.

Ursolic and oleanolic acids as antimicrobial and immunomodulatory compounds for tuberculosis treatment.

Jiménez-Arellanes A, Luna-Herrera J, Cornejo-Garrido J, López-García S, Castro-Mussot ME, Meckes-Fischer M, Mata-Espinosa D, Marquina B, Torres J, Hernández-Pando R.

BMC Complement Altern Med. 2013 Oct 7;13:258. doi: 10.1186/1472-6882-13-258.

10.

[Frontier of mycobacterium research--host vs. mycobacterium].

Okada M, Shirakawa T.

Kekkaku. 2005 Sep;80(9):613-29. Japanese.

PMID:
16245793
11.

In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters.

Xu J, Lu Y, Fu L, Zhu H, Wang B, Mdluli K, Upton AM, Jin H, Zheng M, Zhao W, Li P.

Int J Tuberc Lung Dis. 2012 Aug;16(8):1119-25. doi: 10.5588/ijtld.11.0752. Epub 2012 Jun 12.

PMID:
22691726
12.

Efficacious In Vitro and In Vivo Effects of Dihydrosphingosine-Ethambutol Analogues Against Susceptible and Multi-drug-resistant Mycobacterium tuberculosis.

Olmo ED, Molina-Salinas GM, Bini EI, González-Hernández S, Bustos LA, Escarcena R, Marquina-Castillo B, Mata-Espinosa D, Barrios-Payán J, González-Ramírez D, Fernández SS, San Feliciano A, Hernández-Pando R.

Arch Med Res. 2016 May;47(4):262-70. doi: 10.1016/j.arcmed.2016.07.004.

PMID:
27664485
13.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
14.

Induction of β-defensins by l-isoleucine as novel immunotherapy in experimental murine tuberculosis.

Rivas-Santiago CE, Rivas-Santiago B, León DA, Castañeda-Delgado J, Hernández Pando R.

Clin Exp Immunol. 2011 Apr;164(1):80-9. doi: 10.1111/j.1365-2249.2010.04313.x. Epub 2011 Jan 14.

16.

Progression of chronic pulmonary tuberculosis in mice intravenously infected with ethambutol resistant Mycobacterium tuberculosis.

Srivastava S, Ayyagari A, Dhole TN, Krishnani N, Nyati KK, Dwivedi SK.

Indian J Med Microbiol. 2008 Oct-Dec;26(4):342-8.

17.

Anti-mycobacterial activities of synthetic cationic α-helical peptides and their synergism with rifampicin.

Khara JS, Wang Y, Ke XY, Liu S, Newton SM, Langford PR, Yang YY, Ee PL.

Biomaterials. 2014 Feb;35(6):2032-8. doi: 10.1016/j.biomaterials.2013.11.035. Epub 2013 Dec 4.

PMID:
24314557
18.

Interaction between antimicrobial peptides and mycobacteria.

Gutsmann T.

Biochim Biophys Acta. 2016 May;1858(5):1034-43. doi: 10.1016/j.bbamem.2016.01.031. Epub 2016 Feb 4. Review.

19.

Antitubercular activity and the subacute toxicity of (-)-Licarin A in BALB/c mice: a neolignan isolated from Aristolochia taliscana.

León-Díaz R, Meckes-Fischer M, Valdovinos-Martínez L, Campos MG, Hernández-Pando R, Jiménez-Arellanes MA.

Arch Med Res. 2013 Feb;44(2):99-104. doi: 10.1016/j.arcmed.2012.12.006. Epub 2013 Jan 4.

PMID:
23291382
20.

Targeting Mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides.

Ramón-García S, Mikut R, Ng C, Ruden S, Volkmer R, Reischl M, Hilpert K, Thompson CJ.

Antimicrob Agents Chemother. 2013 May;57(5):2295-303. doi: 10.1128/AAC.00175-13. Epub 2013 Mar 11.

Supplemental Content

Support Center